$4.92
4.02% yesterday
Nasdaq, Dec 24, 07:00 pm CET
ISIN
US29970R1059
Symbol
EVAX

Evaxion Biotech A/S - ADR Stock price

$4.92
-0.43 8.04% 1M
+2.47 100.82% 6M
+0.69 16.39% YTD
+0.45 9.97% 1Y
-81.58 94.31% 3Y
-5.08 50.80% 5Y
-5.08 50.80% 10Y
-5.08 50.80% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.19 4.02%
ISIN
US29970R1059
Symbol
EVAX
Industry

Key metrics

Basic
Market capitalization
$29.9m
Enterprise Value
-
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative | negative
P/S
3.9 | 3.9
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
-13.2%
Return on Equity
639.7%
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
$7.7m | $7.7m
EBITDA
- | $-5.1m
EBIT
$-9.2m | $-10.1m
Net Income
$-5.4m | -
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
131.8% | 129.0%
EBITDA
- | 63.9%
EBIT
38.9% | 31.5%
Net Income
52.7% | -
Free Cash Flow
-
Margin (TTM | estimate)
Gross
-
EBITDA
- | -66.7%
EBIT
-120.3%
Net
-70.9% | -
Free Cash Flow
-
More
EPS
$0.0
FCF per Share
-
Short interest
1.5%
Employees
46
Rev per Employee
$70.0k
Show more

Is Evaxion Biotech A/S - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Evaxion Biotech A/S - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Evaxion Biotech A/S - ADR forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Evaxion Biotech A/S - ADR forecast:

Buy
89%
Hold
11%

Financial data from Evaxion Biotech A/S - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
7.65 7.65
132% 132%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 7.19 7.19
9% 9%
94%
- Research and Development Expense 9.67 9.67
8% 8%
126%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -9.21 -9.21
39% 39%
-120%
Net Profit -5.42 -5.42
53% 53%
-71%

In millions USD.

Don't miss a Thing! We will send you all news about Evaxion Biotech A/S - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Evaxion Biotech A/S - ADR Stock News

Neutral
GlobeNewsWire
6 days ago
COPENHAGEN, Denmark, December 19, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has been informed that MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA) will not exercise its option for Evaxion's Gonorrhea vaccine candidate EVX-B2. Consequently, Evaxion retains global rights to EVX-B2 and will look...
Neutral
GlobeNewsWire
19 days ago
COPENHAGEN, Denmark, December 6, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new data demonstrating that its AML vaccine candidate, EVX-04, triggers strong specific T-cell responses and effectively prevents tumor growth in preclinical models.
Neutral
GlobeNewsWire
about one month ago
COPENHAGEN, Denmark, November 12, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces its financial calendar for 2026 as summarized below:
More Evaxion Biotech A/S - ADR News

Company Profile

Evaxion Biotech A/S discovers and develops novel immunotherapies for cancer and infectious diseases. The company was founded by Niels Iversen Møller and Andreas Holm Mattsson on 11 August, 2008 and is headquartered in Copenhagen, Denmark.

Head office Denmark
CEO Christian Kanstrup
Employees 46
Founded 2008
Website evaxion.ai

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today